

CITATION REPORT

List of articles citing

The impact of hepatitis C burden: an evidence-based approach

DOI: 10.1111/apt.12625

Alimentary Pharmacology and Therapeutics, 2014, 39, 518-31.

Source: <https://exaly.com/paper-pdf/59277699/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
104	Latin American Association for the Study of the Liver Recommendations on Treatment of Hepatitis C. 2014 , 13, S4-S66		20
103	The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. 2014 , 46 Suppl 5, S186-96		53
102	The relationship between hepatitis C virus infection and diabetes: time for a divorce?. 2014 , 60, 1121-3		11
101	Hepatitis C in African Americans. 2014 , 109, 1576-84; quiz 1575, 1585		30
100	Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 657-75	6.1	52
99	The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. 2015 , 6, 126-128		3
98	Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 497-520	6.1	130
97	Association between HCV infection and diabetes type 2 in Egypt: is it time to split up?. 2015 , 25, 918-23		13
96	Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. 2015 , 20, 259-66		4
95	IFN- λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors. 2015 , 87, 1702-15		7
94	Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response. 2015 , 61, 730-40		190
93	What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?. 2015 , 6, 117-119		7
92	Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. 2015 , 61, 1798-808		109
91	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 2015 , 212, 367-77		46
90	The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. 2015 , 8, 298-312		83
89	The role of alexithymia in quality of life impairment in patients with chronic hepatitis C during antiviral treatment. 2015 , 60, 17-25		7
88	The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. 2015 , 160, 1043-54		3

87 Hepatocellular Carcinoma. **2015**, 207-218

86 Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. **2015**, 63, 337-45 116

85 Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. **2015**, 62, 1004-12 48

84 The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17000 HCV-infected transplant recipients. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 209-17 6.1 14

83 Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. **2016**, 28, 187-92 2

82 Chaperones in hepatitis C virus infection. **2016**, 8, 9-35 15

81 Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis C. **2016**, 10, 2119-27 6

80 Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. **2016**, 95, e2482 10

79 Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. **2016**, 63, 1112-9 56

78 Racial diversity in mortality and morbidity in urban patients with hepatitis C. **2016**, 23, 439-46 1

77 Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 385-99 6.1 33

76 Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. **2016**, 23, 623-30 31

75 An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. **2016**, 111, 808-16 75

74 Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. **2016**, 19, 795-805 16

73 Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis. **2016**, 39, 449-457

72 Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States. **2016**, 33, 1316-30 10

71 The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes. **2016**, 23, 53-61 8

70 Altered natural killer cells subsets distribution in children with hepatitis C following vertical transmission. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 125-33 6.1 6

69	Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. 2016 , 19, 544-51		31
68	Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. 2016 , 65, S109-S119		43
67	High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. 2016 , 151, 651-659.e1		77
66	HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 44, 638-43	6.1	38
65	Hepatocellular carcinoma. 2016 , 2, 16018		1274
64	Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. 2016 , 95, e4243		13
63	Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 1060-8	6.1	12
62	[Cost-effectiveness analysis of sofosbuvir, peginterferon and ribavirin in patients with chronic hepatitis C: Early treatment in the initial stage of fibrosis vs. delayed treatment in advanced fibrosis]. 2016 , 39, 449-57		7
61	Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. 2016 , 16, 45		17
60	Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. 2016 , 57, 82-8		20
59	Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of [Prevalence, Quality of Life, and Economic Burden. 2016 , 150, 1599-1608		231
58	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. 2016 , 65, 33-39		86
57	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. 2016 , 64, 301-307		125
56	The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. 2017 , 37 Suppl 1, 7-12		20
55	Health-related quality of Life in patients with chronic hepatitis C receiving Sofosbuvir-based treatment, with and without Interferon: a prospective observational study in Egypt. 2017 , 17, 18		11
54	Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. 2017 , 24, 750-758		8
53	Hepatitis C virus infection. 2017 , 3, 17006		224
52	Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. 2017 , 15, 25		18

51	Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 2017 , 67, 263-271	218
50	Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. 2017 , 37, 1796-1804	28
49	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. 2017 , 2, 494-500	37
48	Global epidemiology and burden of HCV infection and HCV-related disease. 2017 , 14, 122-132	233
47	Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. 2017 , 89, 2181-2187	31
46	Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective. 2017 , 13, 7-15	10
45	Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. 2017 , 96, e5904	106
44	Specialty Care Access Network-Extension of Community Healthcare Outcomes Model Program for Liver Disease Improves Specialty Care Access. 2017 , 62, 3344-3349	12
43	The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data. 2017 , 29, 503-508	2
42	Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project. 2017 , 57, 510-515.e2	21
41	Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study. 2017 , 37, 179-186	29
40	Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract?. 2017 , 2017, 8349150	6
39	Liver transplantation for chronic hepatitis C virus infection in the United States 2002-2014: An analysis of the UNOS/OPTN registry. 2017 , 12, e0186898	12
38	Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway. 2017 , 17, 624	7
37	Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir. 2018 , 16, 567-574.e6	22
36	Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1238-1252	6.1 7
35	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. 2018 , 69, 293-300	90
34	Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. 2018 , 25, 945-951	16

33	Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. 2018 , 17, 815-821		4
32	Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study. 2018 , 30, 1200-1207		12
31	Application of Dendrimers for the Treatment of Infectious Diseases. 2018 , 23,		49
30	The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. 2018 , 17, 377-384		10
29	Clinical relevance of serum non-organ-specific antibodies in patients with HCV infection receiving direct-acting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1138-1145	6.1	6
28	Public Health and Economic Burden of Hepatitis C Infection in Developing Countries. 2018 , 25-32		3
27	Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 440-450	6.1	17
26	Depression among adults with chronic hepatitis C on antiviral treatment in Port-Said, Egypt. 2018 , 26, 679-686		0
25	Hepatitis C Virus Treatment in Non-Liver Organ Transplantation Programs. 2018 , 17, 105-110		
24	Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. 2019 , 39, 54-59		20
23	Emerging Evidence for Infectious Causes of Cancer in the United States. 2019 , 41, 82-96		2
22	Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study. 2019 , 18, 708-714		2
21	Sofosbuvir-Based Regimens for Chronic Hepatitis C in a Well-Insured U.S. Population: Patient Characteristics, Treatment Adherence, Effectiveness, and Health Care Costs, 2013-2015. 2019 , 25, 195-210		8
20	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. 2019 , 19, 300		2
19	Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research. 2019 , 64, 316-323		9
18	Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. 2020 , 18, 468-476.e11		10
17	HCV testing: Order and completion rates among baby boomers obtaining care from seven health systems in Florida, 2015-2017. 2021 , 153, 106222		3
16	Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. 2020 , 73, 1360-1367		7

15	The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data. 2020 , 37, 4709-4719	2
14	Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. 2020 , 10, e035224	5
13	Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. 2021 , 7, 258-263	
12	Opioid use disorder and HCV (hepatitis C virus). 2021 , 77-96	
11	Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. 2016 , 4, 76-82	17
10	Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C. 2018 , 9, 50-58	3
9	Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. 2015 , 21, 12896-953	53
8	Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study. 2020 , 14, 207-217	8
7	. 2016 , 14,	
6	Using the endoscopy suite of an urban medical center for efficient identification of patients with HCV and linkage to care. 2019 , 10, 319-322	
5	Extrahepatic Benefits Achieved With Sustained Virologic Response in Patients With Hepatitis C Virus Infection. 2017 , 13, 553-555	
4	Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report.. <i>Journal of Medical Case Reports</i> , 2021 , 15, 627	1.2 1
3	Does Hepatitis C Independently Increase the Risk of Colorectal Adenoma?. 32-33	0
2	The effect of hepatitis C-associated premature deaths on labour productivity losses in Spain: a ten-year analysis.	0
1	Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. 2022 , 28, 1138-1148	0